Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108

PURPOSE: Aurora A kinase (AAK) is upregulated in highly proliferative lymphomas, suggesting its potential as a therapeutic target. Alisertib is a novel oral AAK inhibitor without adverse safety signals in early-phase studies that demonstrated preliminary activity in T-cell lymphoma. This phase II st...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Barr, Paul M., Li, Hongli, Spier, Catherine, Mahadevan, Daruka, LeBlanc, Michael, Ul Haq, Mansoor, Huber, Bryan D., Flowers, Christopher R., Wagner-Johnston, Nina D., Horwitz, Steven M., Fisher, Richard I., Cheson, Bruce D., Smith, Sonali M., Kahl, Brad S., Bartlett, Nancy L., Friedberg, Jonathan W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4500834/
https://ncbi.nlm.nih.gov/pubmed/26077240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.60.6327
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados